“Esketamine” in Borderline Personality Disorder: A Look Beyond Suicidality
Cureus April 30, 2022 Neethu K Nandan, Puneet K Soni, Ajay K. Parsaik et al. 11 citations
Borderline personality disorder (BPD) is an extremely disabling condition that affects almost every dimension of a patient's life. The S-enantiomer of ketamine (esketamine) was approved by the Food and Drug Administration (FDA) in 2019 in conjunction with an oral antidepressant for the management of treatment-resistant depression (TRD) in adults. Our patient is a 27-year-old female with a...